Assessment of community-level effects of intermittent preventive treatment for malaria in schoolchildren in Jinja, Uganda (START-IPT trial): a cluster-randomised trial. by Staedke, Sarah G et al.
Staedke, SG; Maiteki-Sebuguzi, C; Rehman, AM; Kigozi, SP; Go-
nahasa, S; Okiring, J; Lindsay, SW; Kamya, MR; Chandler, CIR;
Dorsey, G; Drakeley, C (2018) Assessment of community-level effects
of intermittent preventive treatment for malaria in schoolchildren in
Jinja, Uganda (START-IPT trial): a cluster-randomised trial. The
Lancet Global health. ISSN 2214-109X DOI: https://doi.org/10.1016/S2214-
109X(18)30126-8
Downloaded from: http://researchonline.lshtm.ac.uk/4647384/
DOI: 10.1016/S2214-109X(18)30126-8
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
www.thelancet.com/lancetgh   Published online April 13, 2018   http://dx.doi.org/10.1016/S2214-109X(18)30126-8 1
Articles
Assessment of community-level effects of intermittent 
preventive treatment for malaria in schoolchildren in Jinja, 
Uganda (START-IPT trial): a cluster-randomised trial
Sarah G Staedke, Catherine Maiteki-Sebuguzi, Andrea M Rehman, Simon P Kigozi, Samuel Gonahasa, Jaffer Okiring, Steve W Lindsay, 
Moses R Kamya, Clare I R Chandler, Grant Dorsey, Chris Drakeley
Summary
Background Intermittent preventive treatment (IPT) is a well established malaria control intervention. Evidence 
that delivering IPT to schoolchildren could provide community-level benefits is limited. We did a cluster-randomised 
controlled trial to assess the effect of IPT of primary schoolchildren with dihydroartemisinin-piperaquine (DP) on 
indicators of malaria transmission in the community, in Jinja, Uganda.
Methods We included 84 clusters, each comprising one primary school and the 100 closest available households. The 
clusters were randomly assigned 1:1 to receive IPT with DP or standard care (control) by restricted randomisation to 
ensure balance by geography and school type. Children in intervention schools received IPT monthly for up to six 
rounds (June to December, 2014). We did cross-sectional community surveys in randomly selected households at 
baseline and in January to April, 2015, during which we measured participants’ temperatures and obtained finger-
prick blood smears for measurement of parasite prevalence by microscopy. We also did entomological surveys 
1 night per month in households from 20 randomly selected IPT and 20 control clusters. The primary trial outcome 
was parasite prevalence in the final community survey. The primary entomological survey outcome was the annual 
entomological inoculation rate (aEIR) from July, 2014, to April, 2015. This trial is registered at ClinicalTrials.gov, 
number NCT02009215.
Findings Among 23 280 students registered in the 42 intervention schools, 10 079 (43%) aged 5–20 years were enrolled 
and received at least one dose of DP. 9286 (92%) of 10 079 received at least one full course of DP (three doses). 
Community-level parasite prevalence was lower in the intervention clusters than in the control clusters (19% vs 23%, 
adjusted risk ratio 0∙85, 95% CI 0∙73–1∙00, p=0∙05). The aEIR was lower in the intervention group than in the 
control group, but not significantly so (10∙1 vs 15∙2 infective bites per person, adjusted incidence rate ratio 0∙80, 
95% CI 0∙36–1∙80, p=0∙59).
Interpretation IPT of schoolchildren with DP might have a positive effect on community-level malaria indicators and 
be operationally feasible. Studies with greater IPT coverage are needed.
Funding UK Medical Research Council, UK Department for International Development, and Wellcome Trust.
Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY 4.0 license.
Introduction
Over the past decade, reductions in malaria burden have 
been documented worldwide after heavy investment in 
control measures.1 However, in sub-Saharan Africa, gains 
in malaria control in countries with the highest 
transmission have not been consistent.2 In Uganda, the 
burden of malaria remains high, despite upscaled 
distribution of long-lasting insecticide-treated nets and 
use of artemisinin-based combination therapies to 
treat symptomatic malaria.3 In areas of high malaria 
transmission in Uganda, indoor residual spraying is 
substantially more effective than long-lasting insecticide-
treated nets,4 but is expensive and difficult to sustain.5 
Innovative malaria control efforts are needed in areas 
with high, perennial transmission.
Intermittent preventive treatment (IPT) is a well 
established malaria control intervention, recommended 
for use in pregnant women and infants in specific 
settings, and for children younger than 5 years in areas 
of seasonal transmission. The malaria burden in school-
aged children has been underappreciated,6 but a wealth 
of evidence from Uganda and elsewhere suggests that 
IPT of malaria in schoolchildren provides substantial 
health benefits and might improve cognitive function.7–10 
Additionally, parasite prevalence is typically highest in 
school-aged children (although age ranges vary with 
transmission intensity), who serve as reservoirs of 
infection for the onward transmission of malaria to 
mosquitoes.11 Targeted use of chemoprevention in 
school-aged children will benefit individual children7 
and might decrease malaria transmission by reducing 
the infectious reservoir, which would benefit the 
community.9 However, little evidence is available of 
community-level benefits.
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In the School-based Treatment with ACTs to Reduce 
Transmission of malaria (START-IPT) trial, we in vesti-
gated whether IPT for malaria with dihydro artemisinin-
piperaquine (DP) in schoolchildren would affect 
community-level indicators of malaria transmission in 
Jinja district, Uganda. DP is highly efficacious and well 
tolerated, and is more effective than other artemisinin-
based combination therapies in preventing new infections 
because of the long half-life of piperaquine, making it an 
attractive option for IPT.12 We hypothesised that malaria 
transmission, as measured by the prevalence of asexual 
parasitaemia in the community and the annual 
entomological inoculation rate (aEIR), would be reduced 
by the intervention compared with no IPT.
Methods
Study design
START-IPT was a cluster-randomised controlled trial. 
We obtained ethics approval from the Ugandan National 
Council for Science and Technology (reference HS 1530); 
Makerere University School of Medicine Research and 
Ethics Committee, Kampala, Uganda (SBS 145); the 
London School of Hygiene & Tropical Medicine Ethics 
Committee, London, UK (6509); the School of Biological 
and Biomedical Sciences Ethics Committee, Durham 
University, Durham, UK; and the University of 
California, San Francisco Committee on Human 
Research, San Francisco, CA, USA (074826). Sponsorship 
and insurance was provided by the London School of 
Hygiene & Tropical Medicine Clinical Trials Sub-
Committee (reference QA380). The trial was overseen by 
an independent data and safety monitoring board and a 
trial steering committee. We obtained verbal consent 
from schools and written consent from students and 
community residents (with assent from children aged 
≥8 years). 
Study site
Jinja district is an area of perennial malaria transmission 
in eastern Uganda. The district has 11 subcounties that 
range from periurban areas of Jinja town (including 
Walukuba, the only area with an estimated aEIR 
[3∙8 infective bites per person in 2011–1213], but which is 
not representative of the whole district) to rural areas in 
the north, where malaria transmission is more intense. 
All subcounties were eligible for inclusion in the trial.
Clusters and randomisation
We defined cluster boundaries with digitally enumerated 
maps (figure 1, appendix pp 1–2). Each cluster included 
one primary day school and the 100 closest available 
surrounding households. To minimise contamination, we 
implemented a buffer zone of 500 m between clusters. If 
catchment areas for more than one school overlapped, 
Research in context
Evidence before this study
We searched PubMed for original articles published in English 
between Jan 1, 2000, and Oct 1, 2017, with the term 
“intermittent, preventive treatment AND malaria OR 
Plasmodium falciparum AND schoolchildren NOT infant NOT 
pregnancy”. We assessed titles and abstracts and found no 
studies that had investigated the effects of intermittent 
preventive treatment (IPT) for malaria in schoolchildren on 
malaria transmission at the community level. One systematic 
review had assessed the efficacy and safety of IPT in 
schoolchildren. This review included five studies, including 
four individually randomised trials and one cluster-randomised 
trial, which were done in 2002–12 in Kenya, Mali, and Uganda, 
but none reported population-level health effects. Three later 
studies of school-based malaria interventions included one 
individually randomised trial of IPT for malaria and helminths in 
Ghana, one individually randomised trial of IPT for malaria in the 
Democratic Republic of Congo, and one cluster-randomised trial 
of IPT for malaria plus distribution of long-lasting 
insecticide-treated nets in Mali. Again, none assessed 
population-level outcomes. One stepped-wedge, 
cluster-randomised trial in Senegal assessed community-level 
outcomes but with seasonal malaria chemoprevention in 
schoolchildren and not IPT. In that trial, children younger than 
10 years received amodiaquine and sulfadoxine-pyrimethamine, 
administered by community health workers via health posts. 
No reduction in all-cause mortality (the primary outcome) was 
seen, but the incidence of confirmed malaria in community 
residents too old to receive seasonal malaria chemoprevention 
reduced significantly by 26%. These results were encouraging, 
but the intervention, method of assessment, and outcome 
measures differed substantially from those in our trial, 
precluding direct comparisons.
Added value of this study
This study in Jinja, Uganda, makes an important contribution to 
the limited evidence on use of IPT as a tool to reduce malaria 
transmission. The use of dihydroartemisinin-piperaquine for IPT 
of malaria in schoolchildren was associated with reductions in 
parasite prevalence and annual entomological inoculation rate, 
but these were of borderline significance. Intervention coverage, 
however, was lower than expected. 
Implications of all the available evidence
Evidence on the effects of providing IPT of malaria to 
schoolchildren is limited, but promising. Schoolchildren are 
major contributors to the infectious reservoir, and providing 
IPT in schools offers an operationally attractive and potentially 
sustainable intervention that could be integrated with 
currently deployed malaria control methods. Additional 
studies are needed to explore these findings further, including 
assessments of the population-level effects with greater 
intervention coverage.
See Online for appendix
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one school was selected: if a cluster contained public and 
private schools, public schools were prioritised, and if 
schools were the same type, one was chosen randomly. 
Clusters were assigned 1:1 to receive IPT or standard care 
(services typically provided by the Ministries of Health and 
Education; control) in a parallel design. We used restricted 
randomisation to ensure balance across clusters for 
geographical location by subcounty and school type (public 
or private). A simulated data series of 15 000 allocations 
was generated by the trial statistician with Stata/SE 
(version 12.1), which produced a list of 5735 potential 
allocations that met the restriction criteria. Study personnel 
enrolled primary schools after cluster randomisation 
without masking of study group allocation.
IPT intervention
Study personnel met with stakeholders in health and 
education at the national and district levels to build 
awareness and support for the trial. An information 
sheet described the study, and verbal consent to 
participate was obtained from headteachers of schools 
after randomisation. Copies of the school registers were 
obtained from schools in the intervention clusters.
Study personnel initially reviewed eligibility of school-
children in the intervention cluster schools with parents 
and guardians. Eligibility criteria were ability to locate a 
parent or guardian, being enrolled in an intervention 
school, age 5 years or older, no known allergy to DP, no 
menarche, no history of cardiac problems or fainting, no 
family history of long QT syndrome, not currently taking 
medications known to prolong the QT interval, and 
willingness of the parent or guardian to provide written 
informed consent. If these criteria were met, study 
personnel interviewed children individually at school to 
assess the final eligibility criteria: ability to locate the 
student, no menarche, weight 11 kg or greater, and 
provision of written assent by student if aged 8 years or 
older. After screening, students underwent a brief physical 
examination, including measurement of temperature 
(tympanic membrane), height, and weight. We recorded 
participants’ fingerprints to facilitate future identification 
for DP treatment.
The DP preparation was full-strength Duo-Cotexcin 
tablets (Beijing Holley-Cotec Pharmaceuticals, Beijing, 
China), containing 40 mg dihydroartemisinin and 
320 mg piperaquine and taken orally. IPT was delivered to 
students in intervention schools by study personnel, 
with doses given once daily for 3 days per month (one 
round of treatment), according to weight-based guidelines 
(appendix p 3), for up to six rounds of treatment. All 
treatments were directly observed and recorded. 
To assess safety we monitored all intervention 
participants for serious adverse events, and a subset of 
participants selected by convenience sampling for cardiac 
Figure 1: Map of study area
The study included 84 clusters, each including one primary school and the closest available 100 surrounding households. IPT=intermittent preventive treatment.
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monitoring. The relationship of serious adverse events to 
DP was assessed by study staff, and all serious adverse 
events were reported to the institutional review boards 
and the trial’s data and safety monitoring board. Detailed 
results on safety will be reported separately.
Assessments
Cross-sectional community surveys were done in 
households randomly selected from each cluster at 
baseline (March to June, 2014) and after the intervention 
(January to April, 2015). The sampling frame for the 
baseline survey was generated from the digital 
enumeration done to generate clusters, and for the final 
survey from a census of clusters. Each survey was done 
in a different random sample.
Study personnel visited households for both 
community surveys to identify those with an adult 
resident available to do the survey who met the following 
eligibility criteria: a usual resident present on the night 
before the survey, age 18 years or older, and agreement 
to provide written informed consent. Households were 
excluded if the dwelling could not be found or was vacant 
or if no adult resident was at home on more than 
three visits. If selection criteria were met, a household 
questionnaire was administered to the head of the 
household or their designate to gather information on all 
residents, ownership and use of all bednets, and proxy 
indicators of wealth.
The target sample sizes of age groups varied because of 
age-related differences in parasite prevalence. Thus, re-
cruitment of household residents into the community 
clinical surveys was stratified by age. For the baseline 
survey, all members of a household were eligible for 
inclusion. For the final survey, all members of a household 
aged 4 months to younger than 5 years or older than 
15 years were eligible for inclusion, but for residents aged 
5–15 years, only one per household could be included, and 
was chosen at random by random number tables. To 
participate in the clinical survey, household residents were 
reviewed for selection criteria, including being a usual 
resident of the household on the night before the survey, 
ability to locate the resident, appropriate age, provision of 
written informed consent for adults or parents or 
guardians of children, and provision of written assent 
from children aged 8 years and older.
At the time of the survey, we measured each 
participant’s temperature and obtained a finger-prick 
blood sample that was used to prepare a thick blood 
smear to measure haemoglobin concentration with a 
portable spectro photometer (HemoCue, Ängelholm, 
Sweden) in children younger than 5 years. Samples were 
stored on filter paper for future molecular testing. Rapid 
diagnostic testing was done with CareStart Malaria 
HRP2 for Plasmodium falciparum (ACCESSBIO, 
Somerset, NJ, USA) in participants who had fever 
(tympanic mem brane temperature ≥38∙0°C) or history 
of fever in the previous 48 h.
We did an entomological survey in 200 households, 
five per cluster in 20 of the IPT clusters and five 
per cluster in 20 of the control clusters. The clusters and 
households were randomly selected before the survey 
started. Selection criteria were as follows: the ability to 
locate the household; residence in the subcounty for the 
previous 6 months; and provision of written informed 
consent by the head of the household (or designate). 
Participating households were sampled one night per 
month with miniature Centers for Disease Control and 
Prevention light traps (Model 512, John W Hock Company, 
Gainesville, FL, USA). Traps were positioned 1 m above 
the floor at the foot end of the bed where a person slept 
under an insecticide-treated net.
Laboratory procedures
Thick blood smears were stained with 2% Giemsa for 
30 min and read by experienced laboratory technologists 
who were unaware of study group assignments. Parasite 
and gametocyte densities were calculated from thick 
blood smears by counting the number of asexual 
parasites and gametocytes, respectively, per 200 leucocytes 
(or per 500, if the count was less than ten parasites or 
gametocytes per 200 leucocytes), assuming a leucocyte 
count of 8000 cells per μL (8·0 × 10⁹/L). We classified the 
result as negative if examination of 100 high-power fields 
revealed no asexual parasites or gametocytes. For quality 
control, all slides were read by a second microscopist, 
and a third reviewer designated discrepant readings.
DNA was extracted from dried blood samples on filter 
papers by standard methods with Chelex 100 Resin 
(Bio-Rad, Hercules, CA, USA) and analysed by loop-
mediated isothermal amplification (LAMP) for detection 
of P falciparum parasites. Mosquitoes were identified 
taxonomically to species level where possible. Ident-
ification of anophelines was based on established 
morphological criteria, and members of the Anopheles 
gambiae complex were identified by PCR.13 Sporozoites 
were identified with ELISA.13
Outcomes
The primary outcome was prevalence of asexual 
parasitaemia in the final community survey, as measured 
by microscopy of individual blood smears. Secondary 
outcomes were prevalence of parasitaemia by microscopy 
and LAMP, prevalence of gametocytaemia, prevalence of 
anaemia,14 and mean haemoglobin concentration in the 
final community survey. The primary outcome for the 
entomology survey was aEIR, estimated from July, 2014, 
when the intervention began, to April, 2015. Secondary 
entomological outcomes were sporozoite rate and vector 
density per house.
Statistical analysis
The target sample size for the baseline survey was based 
on age-stratified estimates of parasite prevalence from 
Walukuba subcounty in Jinja district.15 The prevalence of 
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Figure 2: Trial profile
IPT=intermittent preventive treatment. DP=dihydroartemisinin-piperaquine. AL=artemether-lumefantrine. *One household was excluded and replaced with a newly recruited household.
86 schools eligible
42 clusters assigned to control 
group
42 clusters (42 primary schools,
23 280 students) in intervention 
group eligible for IPT
42 clusters assigned to IPT group
5204 students excluded
1634 not located
1346 menarche
1142 no consent or assent
328 screening incomplete
43 cardiac history or 
treatment
9 adverse reaction to DP 
or AL
5 age <5 years
2 weight <11 kg
20 other reasons
675 lost to follow-up
20 randomly selected clusters 
(198 households) screened for 
baseline entomological survey
42 clusters (15 283 students) 
screened
42 clusters (10 079 students) 
received IPT
Round 1 2680 (12%)
Round 2 3287 (14%)
Round 3 3601 (15%)
Round 4 8154 (36%)
Round 5 8628 (37%)
Round 6 6714 (29%)
5022 residents included in 
baseline community survey 
    3066 aged <5 years
      641 aged 5–15 years
    1315 aged >15 years
5009 residents included in 
baseline community survey 
3047 aged <5 years
644 aged 5–15 years
1318 aged >15 years
98 households excluded
66 consent not obtained
15 not home or unavailable
17 other reasons
1511 households excluded
1005 houses not located
276 adult not located
157 not interested
73 missing data
16 residents excluded
5 consent not obtained
11 missing data
56 households excluded
39 consent not obtained
8 not home or unavailable
9 other reasons
1482 households excluded
916 house not located
351 adult not located
143 not interested
72 missing data
28 residents excluded (missing 
data)
20 clusters (100 households) 
included in entomological 
survey
20 clusters (100 households*) 
completed entomological 
survey
42 clusters (2957 households) 
screened for baseline 
community survey
42 clusters (1446 households, 
5038 residents) screened for 
baseline community survey
4467 residents included in final 
community survey 
2705 aged <5 years
598 aged 5–15 years
1164 aged >15 years
795 households excluded
79 houses not located 
471 adult not located
121 not interested
124 other reasons
52 residents excluded
25 resident not located
17 consent not obtained
8 parent not located
2 other reasons
42 clusters (2160 households) 
approached for final 
community survey
42 clusters (1365 households, 
4519 residents) screened for 
final community survey
4455 residents included in final 
community survey 
2702 aged <5 years
603 aged 5–15 years
1150 aged >15 years
755 households excluded
83 houses not located 
393 adult not located
127 not interested
152 other reasons
19 residents exclude
1 resident not located
4 consent not obtained
10 parent not located
4 other reasons
42 clusters (2097 households) 
approached for final 
community survey
42 clusters (1342 households, 
4474 residents) screened 
for final community survey
20 randomly selected clusters 
(156 households) screened for 
baseline entomological survey
20 clusters (100 households) 
included in entomological 
survey
20 clusters (100 households) 
completed entomological 
survey
42 clusters (3030 households) 
screened for baseline 
community survey
42 clusters (1548 households, 
5037 residents) screened for 
baseline community survey
2 schools excluded (closed)
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parasitaemia at baseline was assumed to vary with age 
and was estimated to be 4% in children younger than 
5 years, 17% in children aged 5–15 years, and 9% in 
individuals older than 15 years. To detect a relative 
reduction of 35% in the intervention group compared 
with the control group in each age group and in 22% of 
respondents overall, we calculated that we would need to 
recruit 119 individuals per cluster (minimum total 9996), 
including 73 children younger than 5 years, 15 children 
aged 5–15 years, and 31 individuals older than 15 years 
(appendix pp 4–5).
Sample size calculations for the final community 
survey were informed by data collected in the baseline 
survey. Calculations accounted for correlation among 
clusters by calculating the coefficient of variation (k).16 
We conservatively assumed a k value of 0∙5. The number 
of clusters was fixed at 84. Assuming significance of 5% 
and power of 80%, we calculated that 105 individuals per 
cluster (minimum total 8820) would allow detection of a 
relative reduction in parasite prevalence of 29%, based 
on 21% prevalence in the control group. This estimate 
was supported by mathematical modelling estimates17 
that we adapted to simulate the START-IPT trial design 
Control group Intervention group
Households
Total households 
interviewed
1446 1548
Total residents 8348 8640
Mean number of 
residents per 
household
5∙8 (0∙14) 5∙6 (0∙11)
Have electricity 326 (23%) 316 (20%)
Have mobile 
phone
1225 (85%) 1354 (88%)
Head of household education*
No education 164 (11%) 194 (13%)
Primary school 
(P1–6)
702 (49%) 633 (41%) 
Secondary 
school (S1–6)
422 (29%) 531 (34%)
Certificate, 
diploma, 
university
143 (10%) 167 (11%)
Household wealth index†
1 (poorest) 296 (21%) 309 (20%)
2 279 (19%) 312 (20%)
3 259 (18%) 338 (22%)
4 304 (21%) 294 (19%)
5 (least poor) 305 (21%) 292 (19%)
Own at least one 
ITN
1429 (99%) 1533 (99%)
Nets per 
household
2∙3 (0∙12) 2∙4 (0∙12)
Survey participants
Total enrolled
<5 years 3066 3047
5–15 years 641 644
>15 years 1315 1318
Age (years)
<5 years 2∙5 (0∙03) 2∙5 (0∙03)
5–15 years 9∙5 (0∙16) 9∙1 (0∙14)
>15 years 33∙6 (0∙62) 33∙4 (0∙64)
Male/female participants
<5 years 1564 (51%)/1502 (49%) 1563 (51%)/1484 (49%)
5–15 years 346 (54%)/295 (46%) 346 (54%)/298 (46%)
>15 years 863 (66%)/452 (44%) 887 (67%)/431 (33%)
Slept under an ITN the previous night
<5 years 2383 (78%) 2250 (74%)
5–15 years 449 (70%) 449 (70%)
>15 years 1028 (78%) 1014 (77%)
(Table 1 continues in next column)
Control group Intervention group
(Continued from previous column)
Febrile (≥38∙0°C or history of fever in previous 48 h)
<5 years 2041 (67%) 2049 (67%)
5–15 years 339 (53%) 345 (54%)
>15 years 600 (46%) 525 (40%)
Rapid diagnostic test
Done
<5 years 2009 (98%) 2023 (99%)
5–15 years 334 (99%) 330 (96%)
>15 years 572 (95%) 488 (93%)
Positive
<5 years 973 (48%) 978 (48%)
5–15 years 189 (57%) 170 (52%)
>15 years 173 (30%) 129 (26%)
Haemoglobin concentration (g/L)
<5 years 114 (0∙8) 113 (0∙9)
5–15 years 123 (0∙8) 121 (0∙9)
>15 years 130 (0∙8) 130 (0∙9)
Anaemia‡
<5 years 1057 (35%) 1150 (38%)
5–15 years 157 (24%) 187 (29%)
>15 years 351 (27%) 327 (25%)
Parasitaemia (blood slide positive)
<5 years 809 (26%) 806 (27%)
5–15 years 207 (32%) 208 (32%)
>15 years 167 (13%) 180 (14%)
Gametocytaemia (blood slide positive)
<5 years 230 (8%) 238 (8%)
5–15 years 40 (6%) 38 (6%)
>15 years 19 (1%) 14 (1%)
Data are number, number (%), or mean (SE). ITN=insecticide-treated net. *Data 
missing for 15 (1%) control households and 23 (2%) intervention households. 
†Data missing for three (<1%) control households and three (<1%) intervention 
households. ‡Defined as haemoglobin concentration <110 g/L in children <5 years, 
<115 g/L in children aged 5–11 years, <120 g/L in children aged 12–14 years and 
girls and women ≥15 years, and <130 g/L in boys and men aged ≥15 years. 
Table 1: Characteristics of households and participants in baseline 
community survey
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and setting. This relative difference in parasitaemia 
would correspond to an absolute difference in parasite 
prevalence of 6% (21% vs 15%). Additionally, we weighted 
the sample sizes of age groups to ensure 80% power to 
detect a relative difference in parasite prevalence of 
30·0% between study groups for children younger than 
5 years (n=64), 34∙5% for children aged 5–15 years (n=14), 
and 40% for individuals older than 15 years (n=27).
For the entomological survey, we calculated a k value of 
0∙57 for variation between houses, based on preliminary 
data from Uganda (Dorsey G, unpublished). With this 
level of variation, we calculated that five households in 
20 clusters in each study group would be sufficient to 
detect a 50% reduction in aEIR in the IPT group with 
80% power and 5% significance.16
We did all analyses by intention to treat. Thus, all 
community residents were classified as participating 
in the intervention or control irrespective of whether 
they (or their children) received the intervention. For 
all analyses, we used statistical methods that allowed 
for within-cluster correlations, and analysed data with 
STATA/IC version 12.1. All outcomes were assessed at 
the individual level because of the large number of 
clusters per study group.
For binary prevalence outcomes, we used generalised 
linear Poisson models with log link function. We 
compared the effects of the intervention between groups 
with prevalence risk ratios (RRs) and 95% CIs. The 
probability of selection for the final community survey 
was related to the sampling frame, which was determined 
by the expected parasite prevalence in the age categories 
younger than 5 years, 5–15 years, and older than 15 years. 
Therefore, the age structure of the study population was 
not representative of the community population overall. 
To account of this discrepancy, we assigned individuals 
one of three weights based on their age, calculated as the 
inverse of the percentage of people in each age group in 
the census survey. Population estimates of prevalence 
were obtained with svy commands in STATA, with the 
cluster as the primary sampling unit.
The annual human biting rate was calculated as total 
number of female Anopheles spp mosquitoes captured/
number of house-nights of collection × 365∙25 days per 
year. The sporozoite rate was calculated as the number 
of mosquitoes positive for sporozoites / the number of 
mosquitoes tested. The aEIR was the product of the 
annual human biting rate and the sporozoite rate. We 
compared aEIRs between study groups with negative 
binomial regression (to account for overdispersion), 
with random effects for clusters and repeated measures. 
The number of mosquitoes positive for sporozoites was 
used as the outcome with an offset variable of the 
natural log of the number of house-nights of capture 
and having a coefficient constrained to 1. Households 
selected for the entomological survey were randomly 
selected and, therefore, needed no weighting. We did a 
subgroup analysis to assess whether the effect of the 
intervention changed over time in three time periods 
after the intervention was first implemented: 1–3 months 
(July to September, 2014), 4–6 months (October to Dec-
ember, 2014), and 7–10 months (January to April, 2015). 
This trial is registered at ClinicalTrials.gov, number 
NCT02009215.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had final responsibility for 
the decision to submit for publication. 
Results
Of 86 eligible clusters 84 were included in the study 
(figure 2): 42 were assigned to the intervention group and 
42 to control. 72 schools were public and 12 were private 
schools. In the census of cluster households for the final 
community survey, 44 440 individuals were enumerated 
within the study area, among whom 7675 (17%) were 
children younger than 5 years, 14 704 (33%) were children 
aged 5–15 years, and 22 061 (50%) were individuals older 
than 15 years of age. 11 336 (26%) of 44 440 were reported 
to attend primary school, among whom 5480 (48%) 
attended a school within a cluster boundary (12% of the 
cluster population). Population sizes did not differ 
between clusters surrounding public and private schools.
The baseline community survey was done from March 
to June, 2014, and included 2994 households (median per 
cluster 35, range 19–56) and 10 031 participants (119, 
107–123; figure 2). Characteristics were similar across 
study groups (table 1). 2962 (99%) households reported 
owning at least one insecticide-treated net, and 7573 (76%) 
participants reported having slept under a bednet during 
the night before the survey. Prevalence of parasitaemia 
was highest in children aged 5–15 years, followed by 
children younger than 5 years, and individuals older than 
15 years (table 1). Character istics of clusters were also 
Control Intervention
Total clusters 20 20
Total households 101* 100
Mean number of residents per household (SE) 5∙30 (0∙24) 5∙25 (0∙42)
Number of households with floor mainly made of floor 
bricks, cement, or stones (%)
48 (48%) 50 (50%)
Number of households with roof mainly made of metal (%) 98 (97%) 93 (93%)
Number of households with external walls mainly made of 
burnt bricks with plaster (%)
69 (68%) 71 (71%)
Human biting rate† 2330 2206
Sporozoite rate‡ 2∙8% 2∙4%
aEIR§ (cluster median, IQR) 56∙3 (18∙3, 0–73∙1) 61∙5 (0, 0–36∙5)
aEIR=annual entomological inoculation rate. *One household withdrew consent in 2014, and was replaced. †Total 
number of mosquitoes captured / number of nights of collection × 365∙25. ‡Number of mosquitoes positive for 
sporozoites  / number of mosquitoes tested. §Product of the human biting rate and sporozoite rate.
Table 2: Characteristics of households in the baseline entomology survey, April to June, 2014
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similar across study groups. In each study group, 
36 (86%) clusters contained a public school and six (14%) 
private schools. Baseline cluster parasite prevalence 
was similar (median 25∙4%, IQR 13∙4–33∙6 in the 
intervention group and 25∙2%, 10∙1–31∙4 in the control 
group). The entomological survey was completed in all 
200 households selected (figure 2). Characteristics of 
households in the entomological survey did not differ 
between the study groups (table 2).
We recruited children to receive IPT from March to 
December, 2014 (figure 2). 23 280 students were listed on 
the registers for the 42 intervention schools (mean per 
school 554, range 131–1521). 7997 (34%) were not screened 
because a parent or guardian could not be located and an 
additional 5204 (34%) were excluded during screening. 
89 823 doses of DP were administered to 10 079 (43%) 
children from June to December, 2014, among whom 
9286 (92%) received at least one full course of DP. Given 
the rolling recruitment, the number of children enrolled 
in the intervention and available for treatment per round 
increased during the study (table 3), but the proportion 
who received DP in each round varied because of school 
schedules and holidays. IPT treatment was greatest in 
round 5 (Oct 20 to Nov 14, 2014), when 8628 (37%) of 
23 280 children received at least one dose of DP and 
7007 (30%) received all three doses. The proportion of 
children enrolled in the intervention who received all 
three doses for a given round of IPT was high, ranging 
from 69% (2254 of 3287 in round two) to 84% (3032 of 
3601 in round three; table 3).
17 serious adverse events were reported, including two 
deaths (one from a road traffic accident and one from a 
tetanus infection, both unrelated to DP; table 4). Among 
the remaining 15 serious adverse events, two—an allergic 
skin reaction and a case of weakness and loss of 
consciousness after severe abdominal pain that was 
attributed to hypoglycaemia—were judged to be possibly 
related to DP.
Enrolled (n=23 280) Received any dose of DP Received a full course of DP 
(three doses)
Number (%) Median (IQR) 
proportion per 
cluster (%)
Number (%) Median (IQR) 
proportion per 
cluster (%)
Number (%) Median (IQR) 
proportion per 
cluster (%)
Round 1 (June 30–July 25) 2680 (12%) 13% (9–19) 2680 (12%) 13% (9–19) 2210 (9%) 11% (8–16)
Round 2 (July 28–Aug 22) 3290 (14%) 14% (9–20) 3287 (14%) 14% (9–20) 2254 (10%) 9% (6–15)
Round 3 (Aug 25–Sept 19) 3601 (15%) 15% (11–24) 3601 (15%) 15% (11–24) 3032 (13%) 13% (7–18)
Round 4 (Sept 22–Oct 17) 8159 (35%) 36% (29–49) 8154 (35%) 36% (29–49) 6778 (29%) 32% (24–40)
Round 5 (Oct 20–Nov 14) 8634 (37%) 41% (33–49) 8628 (37%) 41% (33–49) 7007 (30%) 33% (23–39)
Round 6 (Nov 17–Dec 12) 6714 (29%) 33% (22–41) 6714 (29%) 33% (22–41) 5110 (22%) 24% (15–33)
23 280 indivuals were registered in the 42 intervention schools. DP=dihydroartemisinin-piperaquine.
Table 3: Enrolment into the intermittent preventive treatment intervention group in 2014, by round and treatment coverage
Age (years) Sex Maximum 
severity
Related to 
DP*
Event outcome
Death after motor vehicle accident 8 Girl Life threatening No Death
Death after tetanus infection 7 Boy Life threatening No Death
Allergic dermatitis (generalised papular rash) 10 Boy Severe Possibly Resolved, without sequelae
Weakness and loss of consciousness after severe abdominal pain 12 Girl Severe Possibly Resolved, without sequelae
Acute gastritis and upper respiratory tract infection 8 Girl Severe Unlikely Resolved, without sequelae
Acute gastritis with moderate dehydration 8 Girl Severe Unlikely Resolved, without sequelae
Severe body weakness†‡ 9, 11, 12, and 13 All girls All severe All unlikely All resolved, without sequelae
Malaria with upper respiratory tract infection 8 Boy Severe Unlikely Resolved, without sequelae
Malaria with gastroenteritis 12 Boy Severe Unlikely Resolved, without sequelae
Multiple fractures after road traffic accident 8 Girl Severe No Resolved, without sequelae
Malaria 7 Boy Severe No Resolved, without sequelae
Malaria, upper respiratory tract infection, and oral candidiasis 7 Boy Severe No Resolved, without sequelae
Malaria and suspected bacteraemia 7 Girl Severe No Resolved, without sequelae
Epigastric pain attributed to peptic ulcer disease‡ 13 Girl Moderate Unlikely Resolved, without sequelae
DP=dihydroartemisinin-piperaquine. *Study staff assessed serious adverse events to determine the suspected relationship to DP. †Four study participants from the same 
school had severe body weakness on the same day after mass administration of azithromycin for trachoma. ‡Two serious adverse events were seen in one participant.
Table 4: Serious adverse events
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The prevalence of parasitaemia by microscopy in the 
final community survey was marginally lower in the 
intervention group than the control group (table 5). 
Results were similar when stratified by age. The overall 
coefficient of variation of prevalence between clusters 
was k=0∙72 (mean 0∙21 [SD 0∙15]), and was lowest for 
children aged 5–15 years in control clusters (k=0∙60), 
followed by individuals older than 15 years in control 
clusters (k=0∙71), and highest for children younger than 
5 years in control clusters (k=0∙73). Parasite prevalence 
was higher when microscopy results were supplemented 
by LAMP testing (weighted by the inverse of the 
population proportion and the probability of LAMP 
sampling), particularly in children aged 5–15 years. In all 
age groups, parasite prevalence by microscopy and 
LAMP was lower in the intervention group than the 
control group, although these differences were not 
significant in the adjusted analysis except for children 
aged 5–15 years (table 5). 
In the entomological survey, 27 034 mosquitoes were 
collected over 1936 nights, of which 6651 were Anopheles 
spp. 6322 (95%) of anophelines collected were A gambiae 
sensu lato, 277 (4%) A funestus, 51 (1%) A arabiensis, and 
one (<0·5%) another species. The number of female 
Anopheles spp mosquitoes, the human biting rate, 
sporozoite rate, and aEIR were all lower in the intervention 
group than in the control group (table 6). Overall, the 
aEIR was 10∙1 infectious bites per person (cluster 
median 0, IQR 0–14∙5) in the intervention clusters versus 
15∙2 (7∙4, 0–19∙6) in the control clusters, but varied 
over time. During the period of peak delivery of DP 
(months 4–6 of the IPT intervention in October to 
December, 2014), the aEIR and sporozoite rate were lower 
in the intervention group than in the control. The overall 
coefficient of variation of the prevalence between clusters 
was k=1∙69.
Discussion
School-aged children are important contributors to the 
human infectious malaria reservoir.11 Given the likelihood 
of operational success and sustainability of school-
based interventions, the question of whether IPT of 
schoolchildren can reduce malaria transmission at the 
population level is highly relevant. In this cluster-
randomised trial, monthly IPT with DP provided to 
children in primary schools in a population with high 
insecticide-treated net coverage was associated with 
reductions in measures of malaria transmission, includ ing 
parasite prevalence in community residents and sporozoite 
rate, compared with in the control group, although these 
differences were of borderline significance. However, 
given that coverage (43%) was substantially lower than 
desired targets, they are notable. Additional studies of IPT 
in schoolchildren to investigate the community-level 
effects with greater IPT coverage are warranted.
Despite an erratic history, chemoprevention is likely 
to be an important addition to existing malaria control 
strategies, partly because of renewed interest in treating 
asymptomatic individuals to reduce transmission. 
Chemo prevention can be delivered in various ways to 
communities, including mass or intermittent screening 
and treatment, mass drug administration, and IPT of 
specific high-risk populations. Mass drug administration 
reduces malaria parasitaemia and transmission,18 and 
WHO recommends mass drug administration in specific 
settings, including elimination campaigns and epi demics, 
Number 
positive of 
total 
respondents
Prevalence Crude risk ratio 
(95% CI)
p value Adjusted risk 
ratio* (95% CI)
p value
Microscopy
All ages†
Control 978 of 4467 23∙1% 1 1
Intervention 791 of 4455 19∙0% 0∙82 (0∙61–1∙12) 0∙21 0∙85 (0∙73–1∙00) 0∙05
<5 years
Control 638 of 2705 23∙6% 1 1
Intervention 533 of 2702 19∙7% 0∙84 (0∙61–1∙15) 0∙27 0∙86 (0∙73–1∙02) 0∙09
5–15 years
Control 196 of 598 32∙8% 1 1
Intervention 150 of 603 24∙9% 0∙76 (0∙55–1∙04) 0∙08 0∙78 (0∙60–1∙00) 0∙05
>15 years
Control 144 of 1164 12∙4% 1 1
Intervention 108 of 1150 9∙4% 0∙76 (0∙53–1∙09) 0∙14 0∙79 (0∙59–1∙05) 0∙11
Microscopy plus LAMP
All ages‡
Control 1419 of 2410 42∙1% 1 1
Intervention 1192 of 2312 37∙5% 0∙89 (0∙72–1∙10) 0∙28 0∙93 (0∙84–1∙04) 0∙18
<5 years
Control 760 of 1156 40∙4% 1 1
Intervention 657 of 1077 37∙1% 0∙92 (0∙73–1∙16) 0∙47 0∙96 (0∙84–1∙09) 0∙50
5–15 years
Control 341 of 598 54∙7% 1 1
Intervention 281 of 603 43∙8% 0∙80 (0∙67–0∙96) 0∙02 0∙84 (0∙73–0∙97) 0∙02
>15 years
Control 318 of 656 42∙7% 1 1
Intervention 254 of 632 34∙6% 0∙81 (0∙64–1∙02) 0∙07 0∙85 (0∙73–1∙00) 0∙06
Prevalence of gametocytaemia
Control 217 of 4467 5∙3% 1 1
Intervention 207 of 4455 5∙1% 0∙95 (0∙64–1∙40) 0∙78 1∙00 (0∙73–1∙37) 0∙99
Prevalence of anaemia§
Control 1083 of 2705 40∙0% 1 1
Intervention 1040 of 2702 38∙5% 0∙96 (0∙80–1∙15) 0∙67 1∙03 (0∙87–1∙23) 0∙72
LAMP=loop-mediated isothermal amplification. *Adjusted for baseline community parasite prevalence (0–13%, 
>13–25%, >25–33%, or >33%), sex, individual bednet use, school type, subcounty, and socioeconomic status quintiles, 
eaves status (all closed, some closed, or all open), window screening status (all, some, or none screened), and latitude 
(<4°, 4 to <5°, or >5°). †Overall prevalence was weighted by the inverse of the percentage of people counted in each age 
group in the cluster census (17∙3% for <5 years, 33∙1% for 5–15 years, and 49∙6% for >15 years). ‡Overall prevalence 
weighted by the inverse of the percentage of the population (17∙3% of children <5 years, 33∙1% of children aged 
5–15 years, and 49∙6% of people >15 years) multiplied by the probability of being sampled for LAMP (the product of the 
percentage negative by microscopy, because only negative samples were eligible for LAMP testing) and an age-related 
probability. Sampling was done in 25% of from children <5 years, 100% of children aged 5–15 years, and 50% of people 
>15 years. §Only measured in children <5 years and was defined as haemoglobin concentration <110 g/L.
Table 5: Effect of intermittent preventive treatment on parasitaemia in the final community survey
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and to control the spread of drug-resistant parasites.19 A 
study of the short-term effects of two rounds of mass drug 
administration with DP in Zambia showed community-
wide reductions in parasite prevalence, particularly in low-
transmission areas.20 Nevertheless, the effects of mass 
drug administration are temporary unless treatment is 
repeated or delivered in the context of highly effective 
vector control,21 raising concerns about feasibility and 
sustainability. The potential for mass drug administration, 
and to a lesser degree other drug-based interventions, to 
suppress naturally acquired immunity and contribute to 
rebound infections and to accelerate the development of 
drug resistance, are other concerns.22 Studies of mass 
screening and antimalarial treatment to individuals who 
tested positive for malaria infection in Burkina Faso and 
Zambia had little effect,23,24 due partly to the poor sensitivity 
of diagnostic tools available for use in field trials.19 
By contrast, IPT of young children, which is highly 
effective against morbidity and mortality and has been 
operationalised as seasonal malaria chemopre vention 
in west Africa, has had a dual effect: in Senegal, chemo-
prevention delivered to children up to age 10 years reduced 
the incidence of malaria in children in the wider 
community by 60% and in older residents by 26%. This 
strategy might, therefore, have a role in transmission 
reduction, particularly if the age range of recipients is 
extended.25 The results from our trial contribute to the 
growing body of evidence of the effectiveness of IPT for 
malaria in older children,7–10 and suggest that reducing 
the infectious reservoir could have positive effects on 
the surrounding community. Operationally, IPT of school-
children is likely to be more feasible than com munity-
based delivery programmes, and should be considered as 
a strategy for malaria control in school-aged children and 
a sustainable approach to reduce transmission. Further 
research is needed to explore feasibility and effects on 
larger scales.
Achieving high coverage is key to the success of 
chemoprevention programmes.18 In this study, coverage 
was well below the target. Several factors contributed to 
the low uptake of the intervention, including community 
perceptions about IPT and the multistep informed 
consent process. We sensitised key stakeholders before 
recruiting study participants by meeting with individuals 
from health and education sectors at the national and 
district levels. We also established a community advisory 
board that included representatives from across Jinja 
district. Nevertheless, we found recruitment of children 
in the 42 intervention schools difficult. Screening was 
done over at least two sessions, first with parents at 
Number of female 
Anopheles spp 
collected
Number of nights 
of collection
Annual density of 
Anopheles spp per 
household
Number of 
mosquitoes 
positive for 
sporozoites
Sporozoite rate aEIR* Adjusted 
incidence rate 
ratio  (95% CI)†
Full period of observation (July, 2014, to April, 2015)
Control 2000 959 762 40 2∙00 15∙2 1
Cluster median (IQR) 54∙5 (7∙0–98∙5) 49∙0 (45∙0–50∙0) 398∙0 (51∙0–776∙0) 1 (0–2∙5) 1∙2 (0–2∙5) 7∙4 (0–19∙6) ∙∙
Intervention 1927 977 720 27 1∙40 10∙1 0∙65 (0∙25–1∙65)
Cluster median (IQR) 24∙0 (9∙0–84∙0) 49∙0 (48∙5–50∙0) 172∙0 (70∙0–622∙0) 0 (0–2) 0 (0–1∙6) 0 (0–14∙5) p=0∙36
First 3 months of IPT (July to September, 2014)
Control 834 300 1015 18 2∙16 21∙9 1
Cluster median (IQR) 11∙0 (1∙5–34∙0) 15∙0 (15∙0–15∙0) 268∙0 (37∙0–828∙0) 0 (0–1) 0∙46 (0–3∙2) 24∙4 (0–24∙4) ∙∙
Intervention 667 301 809 14 2∙10 17∙0 0∙75 (0∙28–2∙04)
Cluster median (IQR) 7∙5 (3∙5–27∙0) 15∙0 (15∙0–15∙0) 183∙0 (88∙0–657∙0) 0 (0–1) 0 (0–3∙1) 0 (0–24∙4) p=0∙58
Final 3 months of IPT (October to December, 2014)
Control 490 258 694 13 2∙65 18∙4 1
Cluster median (IQR) 15∙5 (1∙0–30∙0) 14∙0 (10∙0–15∙0) 426∙0 (37∙0–790∙0) 0 (0–1) 0 (0–3∙4) 0 (0–39∙1) ∙∙
Intervention 467 277 616 5 1∙07 6∙6 0∙36 (0∙10–1∙33)
Cluster median (IQR) 8∙0 (1∙0–23∙0) 14∙5 (14∙0–15∙0) 195∙0 (26∙0–583∙0) 0 (0–0) 0 (0–0) 0 (0–0) p=0∙13
After IPT (January to April, 2015)
Control 676 401 616 9 1∙33 8∙2 1
Cluster median (IQR) 21∙0 (4∙5–48∙5) 20∙0 (20∙0–20∙0) 384∙0 (82∙0–886∙0) 0 (0–1∙0) 0 (0–1∙0) 0 (0–18∙3) ∙∙
Intervention 793 399 726 8 1∙01 7∙3 0∙85 (0∙24–3∙03)
Cluster median (IQR) 7∙5 (3∙5–46∙5) 20∙0 (20∙0–20∙0) 137∙0 (65∙0–849∙0) 0 (0–0) 0 (0–0) 0 (0–0) p=0∙80
aEIR=annual entomological inoculation rate. IPT=intermittent preventive treatment. *Calculated from the household density of infective anophelines. †Adjusted for the main materials of the floor (cement or 
concrete, earth or sand, earth and dung, or other) and external walls (burnt bricks with plaster or other) and cluster. 
Table 6: Effect of the intermittent preventive treatment intervention on entomological inoculation rate in the entomology survey, stratified by time
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parent-teacher association meetings (or at home), followed 
by interviews with students at school. The parent-teacher 
association meetings were poorly attended because 
parents were often at work, and parents or guardians were 
frequently unavailable for home visits and were difficult to 
trace. This experience is similar to that in another school-
based study done in Kenya.26 Additionally, some com-
munity members were initially suspicious of the IPT 
intervention and the motives behind it, as has been seen 
in other studies.18,26 Intensive community engagement 
was needed to address these attitudes, which prolonged 
recruitment but increased success. Inter vention coverage 
increased throughout the study, and might be improved in 
future research projects and IPT programmes by 
streamlining the consent process and including dialogue 
with community members to improve understanding of 
their perspectives and concerns and to address tensions 
and rumours.27 In a pilot study in Malawi, the addition of 
malaria treatment to an existing mass drug administration 
programme for neglected tropical diseases was well 
received, and coverage among children was 87%.28 In 
Uganda, and potentially in other countries, if IPT of 
schoolchildren were to be scaled up to a national 
programme with support of the Ministries of Health and 
Education, community perception and intervention cover-
age might be improved and the challenges of obtaining 
consent minimised.28
We saw no effect of IPT on the secondary outcomes, 
including prevalence of parasitaemia assessed by 
microscopy and LAMP, gametocytaemia, or anaemia. 
Our approach to selecting samples for LAMP assess-
ments, which was done in only 25% of samples negative 
on microscopy in children younger than 5 years and 
50% of negative samples in those older than 15 years, 
might have affected our results. Although we accounted 
for our sampling approach in our analysis of the data, the 
selected samples might not have been representative of 
the population overall. The lack of effect of IPT on low-
density infections identified by LAMP might also reflect 
that IPT works by preventing incident infections rather 
than by treating chronic low-density infections. Gameto-
cytaemia was determined from thick blood smears, 
which is less sensitive than molecular amplification of 
specific sexual stage genes,29 but we did not have the 
resources to do molecular tests. IPT of schoolchildren 
with amodiaquine and sulfadoxine-pyrimethamine in 
Kenya and Mali substantially reduced the prevalence of 
anaemia,9,30 but in Uganda, anaemia is primarily seen in 
children younger than 5 years. The lack of effect on 
anaemia in this study is unsurprising with the low 
coverage of IPT and the multifactorial nature of anaemia, 
in which helminth infections and poor nutrition are 
likely to be important contributing factors.31
This study had several other limitations. First, because 
of the challenges related to recruitment, the number of 
children participating in the intervention group increased 
gradually. Ideally, enrolment would have been completed 
before IPT was started to enable high coverage for all 
six rounds of treatment. Second, attendance at cluster 
schools by children in the school catchment areas was 
surprisingly low, possibly because of travel to school 
and absenteeism. In 2006, 82% of primary-school-aged 
children in Uganda were reported to attend school, but 
absenteeism, particularly in rural areas, was an issue.32 
Clear mapping of catchment areas of schools would 
facilitate improved assessment of intervention effects. 
Third, we opted not to provide a placebo to children 
enrolled in the control schools, which might have 
affected treatment-seeking behaviour of schoolchildren 
or community members. Fourth, our approach to micros-
copy (examining slides at up to 100 high-power fields 
before classifying them as negative) could have lacked 
sensitivity for low-density infections. Examinations at 
magnifications of up to 200 or 500 high-power fields 
might increase sensitivity. Finally, we opted to exclude 
girls at menarche in attempt to avoid administering 
DP in early pregnancy. Although this approach had 
operational advantages, it also denied these girls the 
potential health benefits of IPT and had the unexpected 
consequence of raising suspicion within the community 
regarding the reasons for excluding older girls.
Targeted IPT of schoolchildren with DP as an approach 
to malaria control at the community level in Jinja district, 
Uganda, might have a positive effect on malaria indicators. 
Coverage in our study, however, was lower than expected 
and differences between groups were only of borderline 
significance. This study makes an important contribution 
to the evidence for the use of IPT as a tool to reduce malaria 
transmission. Schoolchildren are major contributors to 
the infectious reservoir. In high transmission areas, 
innovative approaches to malaria control will be needed to 
reduce and ultimately eliminate the burden of malaria. 
IPT of schoolchildren offers an operationally attractive 
and potentially sustainable intervention that could be 
integrated with currently deployed malaria-control 
methods. Future studies should investigate how to achieve 
high coverage, methods to integrate IPT with other school-
based programmes and control measures, the potential 
effects on naturally acquired immunity and risk of 
rebound, and the risk of accelerating antimalarial drug 
resistance.
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